126931-31-5

Basic information

• Product Name: methyl 3-<4-(tert-butoxycarbonyl)phenyl>propanoate
• Synonyms: methyl 3-<4-(tert-butoxycarbonyl)phenyl>propanoate
• CAS NO: 126931-31-5
• Molecular Weight: 264.321
• Mol File: 126931-31-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 3-<4-(tert-butoxycarbonyl)phenyl>propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-<4-(tert-butoxycarbonyl)phenyl>propanoate(126931-31-5)
• EPA Substance Registry System: methyl 3-<4-(tert-butoxycarbonyl)phenyl>propanoate(126931-31-5)

Safety Data

• Hazardous Substances Data: 126931-31-5(Hazardous Substances Data)

Upstream product

• 146943-27-3 methyl 3-<4-(tert-butoxycarbonyl)phenyl>propenoate 
• 120363-13-5 tert-butyl 4-iodobenzoate 
• 619-58-9 4-iodobenzoic acid 
• 65874-27-3 4-(tert-butoxycarbonyl)benzaldehyde 

Downstream Products

• 86208-18-6 3-<4-(tert-butoxycarbonyl)phenyl>propionic acid 
• 146943-43-3 N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid diethyl ester 
• 146943-41-1 4-[3-(2,4-Diamino-6-oxo-1,6-dihydro-pyrimidin-5-yl)-4,4-dimethoxy-butyl]-benzoic acid tert-butyl ester 
• 134373-06-1 4-[4,4-Dimethoxy-3-(2,4,6-triamino-pyrimidin-5-yl)-butyl]-benzoic acid tert-butyl ester 
• 137281-39-1 4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl )ethyl]benzoic acid 
• 134373-01-6 4-(4,4-Dicyano-3-dimethoxymethyl-butyl)-benzoic acid tert-butyl ester 
• 134373-00-5 tert-butyl 4-(4-methoxy-3-butenyl)benzoate 
• 134372-99-9 3-(4-<2,2-dimethylethyl>carboxyphenyl)-1-propanal 
• 126931-32-6 tert-Butyl 4-(3-hydroxy-1-propyl)benzoate 

Relevant articles and documents

Integrin antagonists

This invention relates to novel heterocycles which are useful as antagonists of the αvβ3 integrin, the α2bβ3 integrin, and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Fused pyrimidines, their production and use

New fused pyrimidines of the general formula (I): STR1 wherein the ring A is a pyridine ring which may be hydrogenated or a benzene ring which may be hydrogenated, X is an amino group or a hydroxyl group, R1, R2, R3 and R